Alkermes
As of the edition of 20 October 2026, Alkermes runs 13 drugs, 4 of them marketed; it is on route A at 1 target and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 3 |
| Went quiet | 4 |
| Stopped | 2 |
| Total | 13 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Naltrexone | none listed | 6 |
| Oxybate | Ends 2028 (exclusivity) | 2 |
| Samidorphan | none listed | 0 |
| Aripiprazole lauroxil | Ends 2030 (patent) | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 3 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Alkermes needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 41 trials led
- Nervous system: 8 trials led
- Chemically induced: 6 trials led